British Columbia Cancer Agency: Prostatic Neoplasms trials

The registry lists 29 Prostatic Neoplasms studies with British Columbia Cancer Agency as lead sponsor. 3 are open to participants now and 3 have results posted.

Phase 2 7Phase 3 3No phase 19(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate CancerRecruitingNCT06200974
• Optimizing Prostate Cancer Treatment in Men With Advanced Local DiseaseRecruitingNCT03836196Not applicable
• Partial Prostate Salvage High Dose Rate BrachytherapyRecruitingNCT03246802Not applicable
• MSG Use With 18F-DCFPyL PET/CT ImagingCompletedNCT03693742Not applicableResults posted
• High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic NoduleCompletedNCT01605097Not applicableResults posted
• CT-validation of Ultrasound Based Planning for High Dose Rate (HDR) Prostate Brachytherapy Using VitesseCompletedNCT01248741Not applicableResults posted
• 68Ga-HTK03149 for Use as a Diagnostic RadiopharmaceuticalStatus unknownNCT04831307Not applicable
• Dynamic Whole Body PET/ MRIWithdrawnNCT04495959
• [68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate CancerActive, not recruitingNCT04484701
• Dynamic Whole Body Positron Emission Tomography/Computed Tomography ImagingStatus unknownNCT04017104
• US-CT Fusion for Post Implant DosimetryCompletedNCT03692104
• LDR vs. HDR Brachytherapy for Prostate CancerActive, not recruitingNCT03426748Not applicable
• PSMA PET/CT for Assessment of Recurrent Prostate CancerActive, not recruitingNCT02899312
• Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate CancerActive, not recruitingNCT02692105Phase 3
• C-arm Cone-beam CT in Prostate BrachytherapyStatus unknownNCT02322931Not applicable
• Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate CancerStatus unknownNCT02254785Phase 2
• Sequencing Abiraterone and Enzalutamide in mCRPCCompletedNCT02125357Phase 2
• Living Well on Androgen Deprivation TherapyWithdrawnNCT02108613Not applicable
• Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR BrachytherapyActive, not recruitingNCT01936883Not applicable
• 18F-NaF PET Imaging for Bone ScintigraphyCompletedNCT01930812Phase 3
• Focal Therapy for Prostate Cancer - A Pilot Study of Focal Low Dose Rate BrachytherapyStatus unknownNCT01830166Not applicable
• Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)WithdrawnNCT01630967Phase 2
• Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate BrachytherapyCompletedNCT01446991Phase 2
• Ability of a New Design of Iodine 125 Seed to Maintain Intended Position When Implanted in the ProstateCompletedNCT01174017Phase 3
• OGX-427 in Castration Resistant Prostate Cancer PatientsCompletedNCT01120470Phase 2
• Intraprostatic MAXimal Simultaneous BoostTerminatedNCT00798837Not applicable
• Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.CompletedNCT00757692Phase 2
• Intensity Modulated Versus Interstitial - Radiation TherapyStatus unknownNCT00407875Not applicable
• Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel ChemotherapyCompletedNCT00407251Phase 2